Mosaic ImmunoEngineering, Inc. (CPMV)
OTCMKTS · Delayed Price · Currency is USD
0.6950
0.00 (0.00%)
May 20, 2026, 9:30 AM EST
Mosaic ImmunoEngineering Company Description
Mosaic ImmunoEngineering Inc., a development-stage biotechnology company, focuses on developing and commercializing immunomodulator platform technology for the treatment of cancer and infectious diseases in humans and for veterinary use.
It offers MIE-101, a nanoparticle-based treatment derived from cowpea mosaic virus, which is non-infectious in mice, dogs, and humans.
The company was founded in 2020 and is based in Novato, California.
Mosaic ImmunoEngineering, Inc.
| Country | United States |
| Founded | 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Steven King |
Contact Details
Address: 9114 Adams Avenue Huntington Beach, California California United States | |
| Phone | 657-208-0890 |
Stock Details
| Ticker Symbol | CPMV |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US61945M1018 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Steven W. King | Chairman of the Board, President, Chief Financial Officer and Chief Executive Officer |
| Paul J. Lytle CPA | Secretary |
| Joseph S. Shan M.P.H. | Head of Clinical Operations |
| Dr. Marvin R. Garovoy M.D. | Head of Medical Immuno-Oncology |
| Cyril Empig Ph.D. | Head of Vaccine Development |